Tests focal radiation treatment for selected low-risk prostate cancer
Tests a focused radiation implant in adults with selected low-risk prostate cancer.
Plain-language title generated from the registry record
Registry title: Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
Key facts
- Where
- Erlangen, GermanySee the site
- Phase
- Phase 2
Where in Germany
- University HospitalErlangen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Erlangen-Nürnberg Medical School
- Trial code
- NCT02391051
- Record updated
- 11 August 2017
- Original description
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.Read full original descriptionShow less
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
Inclusion: Age > 18; Histologically confirmed prostate cancer; Gleason Score of index lesion ≤ 6 (3+3); Tumor stage: cT1-2a cN0 cM0; Unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant lesion contralateral. No more than 25% of the punch should be affected. Therefore a 3D-TPM-biopsy is mandatory before treatment; PSA ≤ 10/ng/ml; Prostate volume < 60 m\^3; No distant metastasis; Life expectancy > 10 years; Informed consent.
Exclusion: Coagulation disorder; Tumor stage ≥ T2b; Known metastasis: N+ and/or M1; General anesthesia or peridural anesthesia is not possible.